Terms: = Leukemia AND GATA2, NFE1B, 2624, ENSG00000179348, MGC2306, P23769
394 results:
1. An intricate regulatory circuit between FLI1 and GATA1/gata2/LDB1/ERG dictates erythroid vs. megakaryocytic differentiation.
Wang C; Hu M; Yu K; Liu W; Hu A; Kuang Y; Huang L; Gajendran B; Zacksenhaus E; Xiao X; Ben-David Y
Mol Med Rep; 2024 Jun; 29(6):. PubMed ID: 38695236
[TBL] [Abstract] [Full Text] [Related]
2. [Gene Profile and Clinical Significance of Concomitant Mutations in CN-AML Patients with
Zhu J; Kang YF; Gao Y; Wang HW; Hao ZH; Wang HW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):335-341. PubMed ID: 38660833
[TBL] [Abstract] [Full Text] [Related]
3. [Clinical Characteristics and Prognosis of Acute Myeloid leukemia Patients with
Shan RQ; Huang S; Gu ZY; Wang N; Liu DH; Dou LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):327-334. PubMed ID: 38660832
[TBL] [Abstract] [Full Text] [Related]
4. PML::RARA and gata2 proteins interact via DNA templates to induce aberrant self-renewal in mouse and human hematopoietic cells.
Katerndahl CDS; Rogers ORS; Day RB; Xu Z; Helton NM; Ramakrishnan SM; Miller CA; Ley TJ
Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2317690121. PubMed ID: 38648485
[TBL] [Abstract] [Full Text] [Related]
5. FLI1 induces erythroleukemia through opposing effects on UBASH3A and UBASH3B expression.
Wang J; Wang C; Hu A; Yu K; Kuang Y; Gajendran B; Zacksenhaus E; Sample KM; Xiao X; Liu W; Ben-David Y
BMC Cancer; 2024 Mar; 24(1):326. PubMed ID: 38461240
[TBL] [Abstract] [Full Text] [Related]
6. Pathogenic gata2 genetic variants utilize an obligate enhancer mechanism to distort a multilineage differentiation program.
Katsumura KR; Liu P; Kim JA; Mehta C; Bresnick EH
Proc Natl Acad Sci U S A; 2024 Mar; 121(10):e2317147121. PubMed ID: 38422019
[TBL] [Abstract] [Full Text] [Related]
7. Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth.
Kellaway SG; Potluri S; Keane P; Blair HJ; Ames L; Worker A; Chin PS; Ptasinska A; Derevyanko PK; Adamo A; Coleman DJL; Khan N; Assi SA; Krippner-Heidenreich A; Raghavan M; Cockerill PN; Heidenreich O; Bonifer C
Nat Commun; 2024 Feb; 15(1):1359. PubMed ID: 38355578
[TBL] [Abstract] [Full Text] [Related]
8. [Suspicion of constitutional abnormality at diagnosis of childhood leukemia: Update of the leukemia committee of the French Society of Childhood Cancers].
Strullu M; Cousin E; de Montgolfier S; Fenwarth L; Gachard N; Arnoux I; Duployez N; Girard S; Guilmatre A; Lafage M; Loosveld M; Petit A; Perrin L; Vial Y; Saultier P
Bull Cancer; 2024 Mar; 111(3):291-309. PubMed ID: 38267311
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic impact of CEBPA mutational subgroups in adult AML.
Georgi JA; Stasik S; Kramer M; Meggendorfer M; Röllig C; Haferlach T; Valk P; Linch D; Herold T; Duployez N; Taube F; Middeke JM; Platzbecker U; Serve H; Baldus CD; Muller-Tidow C; Haferlach C; Koch S; Berdel WE; Woermann BJ; Krug U; Braess J; Hiddemann W; Spiekermann K; Boertjes EL; Hills RK; Burnett A; Ehninger G; Metzeler K; Rothenberg-Thurley M; Dufour A; Dombret H; Pautas C; Preudhomme C; Fenwarth L; Bornhäuser M; Gale R; Thiede C
Leukemia; 2024 Feb; 38(2):281-290. PubMed ID: 38228680
[TBL] [Abstract] [Full Text] [Related]
10. Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome.
Arai H; Matsui H; Chi S; Utsu Y; Masuda S; Aotsuka N; Minami Y
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203823
[TBL] [Abstract] [Full Text] [Related]
11. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
Birdwell CE; Fiskus W; Kadia TM; Mill CP; Sasaki K; Daver N; DiNardo CD; Pemmaraju N; Borthakur G; Davis JA; Das K; Sharma S; Horrigan S; Ruan X; Su X; Khoury JD; Kantarjian H; Bhalla KN
Leukemia; 2024 Mar; 38(3):545-556. PubMed ID: 38086946
[TBL] [Abstract] [Full Text] [Related]
12. Differential co-expression network analysis elucidated genes associated with sensitivity to farnesyltransferase inhibitor and prognosis of acute myeloid leukemia.
Kelesoglu N; Kori M; Yilmaz BK; Duru OA; Arga KY
Cancer Med; 2023 Dec; 12(24):22420-22436. PubMed ID: 38069522
[TBL] [Abstract] [Full Text] [Related]
13. Linking gata2 to myeloid dysplasia and complex cytogenetics in adult myelodysplastic neoplasm and acute myeloid leukemia.
Robbins DJ; Pavletich TS; Patil AT; Pahopos D; Lasarev M; Polaki US; Gahvari ZJ; Bresnick EH; Matson DR
Blood Adv; 2024 Jan; 8(1):80-92. PubMed ID: 38029365
[TBL] [Abstract] [Full Text] [Related]
14. Cytogenetics in the management of bone marrow failure syndromes: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Cuccuini W; Collonge-Rame MA; Auger N; Douet-Guilbert N; Coster L; Lafage-Pochitaloff M
Curr Res Transl Med; 2023; 71(4):103423. PubMed ID: 38016422
[TBL] [Abstract] [Full Text] [Related]
15. Dysregulated expression of gata2 and GATA6 transcription factors in adenomyosis: implications for impaired endometrial receptivity.
Pavlovic ZJ; Hsin-Yu Pai A; Hsiao TT; Yen CF; Alhasan H; Ozmen A; New EP; Guo X; Imudia AN; Guzeloglu-Kayisli O; Lockwood CJ; Kayisli UA
F S Sci; 2024 Feb; 5(1):92-103. PubMed ID: 37972693
[TBL] [Abstract] [Full Text] [Related]
16. Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation.
Williams LS; Williams KM; Gillis N; Bolton K; Damm F; Deuitch NT; Farhadfar N; Gergis U; Keel SB; Michelis FV; Panch SR; Porter CC; Sucheston-Campbell L; Tamari R; Stefanski HE; Godley LA; Lai C
Transplant Cell Ther; 2024 Mar; 30(3):255-267. PubMed ID: 37913908
[TBL] [Abstract] [Full Text] [Related]
17. Germline Predisposition to Myeloid Neoplasms: Diagnostic Concepts and Classifications.
Obiorah IE; Upadhyaya KD; Calvo KR
Clin Lab Med; 2023 Dec; 43(4):615-638. PubMed ID: 37865507
[TBL] [Abstract] [Full Text] [Related]
18. A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice.
Rajagopalan A; Feng Y; Gayatri MB; Ranheim EA; Klungness T; Matson DR; Lee MH; Jung MM; Zhou Y; Gao X; Nadiminti KV; Yang DT; Tran VL; Padron E; Miyamoto S; Bresnick EH; Zhang J
J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 37847561
[TBL] [Abstract] [Full Text] [Related]
19. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia.
Eckardt JN; Stasik S; Röllig C; Petzold A; Sauer T; Scholl S; Hochhaus A; Crysandt M; Brümmendorf TH; Naumann R; Steffen B; Kunzmann V; Einsele H; Schaich M; Burchert A; Neubauer A; Schäfer-Eckart K; Schliemann C; Krause SW; Herbst R; Hänel M; Hanoun M; Kaiser U; Kaufmann M; Rácil Z; Mayer J; Oelschlägel U; Berdel WE; Ehninger G; Serve H; Müller-Tidow C; Platzbecker U; Baldus CD; Dahl A; Schetelig J; Bornhäuser M; Middeke JM; Thiede C
Leukemia; 2023 Dec; 37(12):2395-2403. PubMed ID: 37833543
[TBL] [Abstract] [Full Text] [Related]
20. TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing gata2 expression.
Heyes E; Wilhelmson AS; Wenzel A; Manhart G; Eder T; Schuster MB; Rzepa E; Pundhir S; D'Altri T; Frank AK; Gentil C; Woessmann J; Schoof EM; Meggendorfer M; Schwaller J; Haferlach T; Grebien F; Porse BT
Nat Commun; 2023 Oct; 14(1):6185. PubMed ID: 37794021
[TBL] [Abstract] [Full Text] [Related]
[Next]
